Interaction of Hepatitis B Virus X Protein with the Pregnane X Receptor Enhances the Synergistic Eff

来源 :临床与转化肝病杂志(英文版) | 被引量 : 0次 | 上传用户:wanmei_zxn
下载到本地 , 更方便阅读
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读
Background and Aims: Hepatitis B virus (HBV) infec-tion has been found to increase hepatocellular sensitivity to carcinogenic xenobiotics, by unknown mechanisms, in the generation of hepatocellular carcinoma. The pregnane X receptor (PXR) is a key regulator of the body\'s defense against xenobiotics, including xenobiotic carcinogens and clinical drugs. In this study, we aimed to investigate the molecular mechanisms of HBV X protein (HBx)-PXR sign-aling in the synergistic effects of chemical carcinogens in HBV-associated hepatocarcinogenesis. Methods: The ex-pression profile of PXR-cytochrome p4503A4 (CYP3A4) signaling was determined by PCR, western blotting, and tissue microarray. Cell viability and aflatoxin B1 (AFB1) cytotoxicity were measured using the cell counting kit-8 assay. Target gene expression was evaluated using tran-sient transfection and real time-PCR. The genotoxicity of AFB1 was assessed in newborn mice with a single dose of AFB1. Results: HBx enhanced the hepatotoxicity of AFB1 by activating CYP3A4 and reducing glutathione S-transferase Mu 1 (GSTM1) in cell lines. Activation of PXR by pregnenolone 16α-carbonitrile increased AFB1-induced liver tumor incidence by up-regulating oncogenic KRAS to enhance interleukin (IL)-11:IL-11 receptor subunit alpha-1 (IL11RA-1)-mediated inflammation in an HBx transgenic model. Conclusions: Our finding regarding AFB1 toxic-ity enhancement by an HBx-PXR-CYP3A4/ GSTM1-KRAS-IL11:IL11RA signaling axis provides a rational explanation for the synergistic effects of chemical carcinogens in HBV infection-associated hepatocarcinogenesis.
其他文献
目的 探讨郑州市35~55岁健康体检职工冠状动脉粥样硬化性心脏病(CHD)的危险因素.方法 收集2018年10月至2019年7月5 915例在郑州市某医院健康体检的33~55岁职工的体检报告及与CH
目的评价抗感染专业临床药师参与全院碳青霉烯类抗菌药物管理的效果,为进一步优化碳青霉烯类抗菌药物管理模式提供参考。结果以2015年10月至2017年9月使用碳青霉烯类抗菌药物治疗的患者(113例)为对照组;2017年10月至2019年9月使用碳青霉烯类抗菌药物治疗的患者(410例)为干预组,此阶段严格落实碳青霉烯类抗菌药物相关管理规定,并增加了抗感染专业临床药师的干预与管理。比较两组的用药合理性评价结果(适应证合理率、单次给药剂量合理率、给药频次合理率、治疗疗程合理率、病原学送检率)和经济指标(碳青霉烯类抗
目的 分析2017-2020年度周口市流感样病例(ILI)的监测结果,为制定流感防控措施提供依据.方法 收集中国流感监测信息报告管理系统中2017-2020年度周口市2家哨点医院的ILI监测
Hepatocellular carcinoma (HCC) accounts for approximately 90% of primary liver cancers and represents a major global health problem. The main risk factors respon
期刊
目的 探讨胃癌组织中白介素6(IL-6)、STT3A和程序性死亡受体配体1(PD-L1)的表达及临床意义.方法 收集2017年1月至2019年12月90例胃癌及相应癌旁组织石蜡标本,采用免疫组织化
Biliary tract cancers (BTCs) comprise a group of hetero-geneous poor prognosis cancers with increasing incidence recent years. The combination chemotherapy with
药物上市的根本目的是解决患者的需求。药物研发应以患者需求为核心,以临床价值为导向,已成为普遍共识。对于肿瘤患者,临床治疗需求急迫,因此抗肿瘤药物研发更应着眼于对患者需求的回应,将以患者为核心的研发理念贯穿于研发始终。在抗肿瘤药物确立研发立题之初,应积极收集、倾听患者的声音;在临床试验设计中,应体现对患者获益保障的设计理念;而在临床试验的开展过程中,也可以采取和融入更多体现对受试者关怀的新型临床试验方式,最终实现抗肿瘤药物的科学合理研发,实现肿瘤患者获益的最大化。
目的 探讨葡萄糖转运蛋白1(Glut1)在肝细胞癌(HCC)中的表达和预后价值,为HCC精准管理探索可靠的预后生物标记物.方法 下载癌症基因组图谱数据库肝细胞癌数据集(TCGA-LIHC)中
The ongoing coronavirus disease-2019 (COVID-19) pan-demic has necessitated special considerations in the man-agement of diseases. The way presence of pre-existi
Nonalcoholic fatty liver disease (NAFLD) is one of the most common causes of chronic liver disease in the world. The rising prevalence of nonalcoholic steatohep